Marksans Pharma

Who are the top shareholders of the Marksans Pharma?

The top shareholders of Marksans Pharma include Mark Saldanha with 43.8%, Orbimed Asia IV Mauritius FVCI Limited at 10.88%, and various foreign institutional investors owning 22.2%. Additionally, mutual funds hold 3.37%, while individual investors account for 25.77% of the shares, with no pledged promoter holdings reported.

The top shareholders of Marksans Pharma include a mix of promoters and institutional investors. The largest shareholder is Mark Saldanha, who holds 43.8% of the company's shares. Other significant shareholders include Orbimed Asia IV Mauritius FVCI Limited, which holds 10.88%, and various foreign institutional investors (FIIs) who collectively own 22.2% of the company through 135 different entities. Additionally, mutual funds hold 3.37% across 9 schemes, while individual investors account for 25.77% of the shareholding. There are no pledged promoter holdings reported.

What does Marksans Pharma do?

Marksans Pharma Ltd is a mid-cap pharmaceutical company involved in the research, manufacture, and sale of pharmaceutical formulations. As of March 2025, it reported net sales of ₹708 Cr and a net profit of ₹91 Cr, with a market cap of ₹11,504 Cr.

Overview: <BR>Marksans Pharma Ltd is engaged in the research, manufacture, marketing, and sale of pharmaceutical formulations within the Pharmaceuticals & Biotechnology industry, classified as a mid-cap company.<BR><BR>History: <BR>Marksans Pharma Limited was incorporated in April 1982 as Tasc Pharmaceuticals Limited and changed its name following a Scheme of Amalgamation on October 10, 2005. The latest quarterly results report net sales and profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 708 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 91 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 11,504 Cr (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 31.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.23% <BR>Debt-Equity: -0.16 <BR>Return on Equity: 15.43% <BR>Price to Book: 4.74 <BR><BR>Contact Details: <BR>Address: 11th Flr GRANDEUR Oshiwara, Veera Desai Extn Rd Andheri(W) Mumbai Maharashtra : 400053 <BR>Tel: 91-22-40012000 <BR>Email: companysecretary@marksanspharma.com <BR>Website: http://www.marksanspharma.com

When is the next results date for Marksans Pharma?

No Upcoming Board Meetings

Who are in the management team of Marksans Pharma?

As of March 2022, the management team of Marksans Pharma includes Mark Saldanha (Chairman & Managing Director), Sandra Saldanha and Varddhman Vikramaditya Jain (Whole-time Directors), along with several Non-Executive and Independent Directors. They oversee the company's strategic direction and governance.

As of March 2022, the management team of Marksans Pharma includes the following individuals:<BR><BR>1. Mark Saldanha - Chairman & Managing Director<BR>2. Harshavardhan Panigrahi - Company Secretary & Compliance Officer<BR>3. Seetharama Raju Buddharaju - Non-Executive & Independent Director<BR>4. Sandra Saldanha - Whole-time Director<BR>5. Digant Mahesh Parikh - Non-Executive & Independent Director<BR>6. Varddhman Vikramaditya Jain - Whole-time Director<BR>7. Abhinna Sundar Mohanty - Non-Executive & Independent Director<BR>8. Sunny Sharma - Director<BR>9. Shailaja Vardhan - Independent Director<BR><BR>This team is responsible for the strategic direction and governance of the company.

Has Marksans Pharma declared dividend?

Marksans Pharma Ltd has declared a 60% dividend, amounting to ₹0.6 per share, with an ex-date of September 17, 2024. While the last 6 months showed a price decline of 25.33%, longer-term returns over 1 to 5 years indicate significant growth, particularly in price returns.

Marksans Pharma Ltd has declared a 60% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 60%<BR>- Amount per share: 0.6<BR>- Ex-date: Sep-17-2024<BR><BR>Dividend Yield: 0.23%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -25.33%, with a dividend return of 0%, resulting in a total return of -25.33%.<BR><BR>Over the past year, the price return was 67.19%, with a dividend return of 0.39%, leading to a total return of 67.58%.<BR><BR>In the 2-year period, the price return was 183.54%, with a dividend return of 0.66%, culminating in a total return of 184.2%.<BR><BR>For the 3-year period, the price return was 452.34%, with a dividend return of 3.27%, resulting in a total return of 455.61%.<BR><BR>In the last 4 years, the price return was 253.48%, with a dividend return of 1.83%, leading to a total return of 255.31%.<BR><BR>Over the past 5 years, the price return was 698.11%, with a dividend return of 4.81%, culminating in a total return of 702.92%.<BR><BR>Overall, Marksans Pharma has declared a substantial dividend, and while the recent 6-month performance shows a decline, the longer-term returns over 1 to 5 years indicate significant growth, particularly in price returns.

Who are the peers of the Marksans Pharma?

Marksans Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, P & G Health Ltd, Ami Organics, Akums Drugs, Shilpa Medicare, and Aarti Pharma. Marksans Pharma has a 1-year return of 75.20%, with strong performance relative to peers, while Ami Organics leads with an 86.50% return.

Peers: The peers of Marksans Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, P & G Health Ltd, Ami Organics, Akums Drugs, Shilpa Medicare, and Aarti Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and P & G Health Ltd, while Good management risk is found at Divi's Lab., Torrent Pharma, Marksans Pharma, and the rest. Average management risk is noted at Ami Organics, Akums Drugs, Shilpa Medicare, and Aarti Pharma. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Marksans Pharma, P & G Health Ltd, Akums Drugs, Shilpa Medicare, and the rest. Good growth is reported at Ami Organics and Aarti Pharma. Excellent capital structure is present at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Marksans Pharma, P & G Health Ltd, Ami Organics, and Aarti Pharma, while Good capital structure is found at Torrent Pharma and Akums Drugs, and Below Average capital structure is noted at Shilpa Medicare.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Ami Organics at 86.50%, while the peer with the lowest is Akums Drugs, which has no available data. Marksans Pharma's 1-year return is 75.20%, indicating a strong performance compared to most peers. Additionally, the six-month return is negative for Marksans Pharma, Torrent Pharma, and Shilpa Medicare.

How big is Marksans Pharma?

As of 24th July, Marksans Pharma Ltd has a market capitalization of 10,890.00 Cr, with net sales of 2,622.85 Cr and a net profit of 380.58 Cr reported in the latest four quarters.

As of 24th July, Marksans Pharma Ltd has a market capitalization of 10,890.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, Marksans Pharma reported net sales of 2,622.85 Cr and a net profit of 380.58 Cr.<BR><BR>For the reporting period of March 2025, the company had shareholder's funds amounting to 2,466.91 Cr and total assets of 3,239.63 Cr.

Is Marksans Pharma overvalued or undervalued?

As of October 10, 2025, Marksans Pharma is considered overvalued with a PE ratio of 23.52 and a year-to-date decline of 38.65%, contrasting with the Sensex's 5.58% return.

As of 10 October 2025, Marksans Pharma's valuation grade has moved from fair to expensive, indicating that the company is currently overvalued. The key ratios reflect this assessment, with a PE ratio of 23.52, an EV to EBITDA of 15.66, and a PEG ratio of 4.80. Compared to its peers, Marksans Pharma's valuation appears high; for instance, Sun Pharma has a PE ratio of 34.96, while Cipla is more attractively valued at a PE of 23.39.<BR><BR>Given these metrics, Marksans Pharma is overvalued in the current market context. The company's recent stock performance shows a significant decline year-to-date at -38.65%, contrasting sharply with the Sensex return of 5.58% during the same period, further supporting the notion that the stock may not be a favorable investment at this time.

Is Marksans Pharma technically bullish or bearish?

As of November 13, 2025, Marksans Pharma's technical trend is mildly bearish, supported by daily moving averages and Bollinger Bands, despite some mixed signals from weekly indicators.

As of 13 November 2025, the technical trend for Marksans Pharma has changed from sideways to mildly bearish. The current stance is bearish, with key indicators driving this assessment including the daily moving averages showing a mildly bearish trend and the Bollinger Bands indicating a mildly bearish position on both weekly and monthly time frames. Although the weekly MACD and KST are mildly bullish, the overall monthly indicators, including MACD and KST, are mildly bearish, reinforcing the bearish sentiment. The RSI on the weekly is bullish but lacks confirmation from the monthly signal, contributing to a mixed outlook. Overall, the strength of the bearish trend is moderate, influenced by the recent price action and the broader context of the stock's performance compared to the Sensex.

How has been the historical performance of Marksans Pharma?

Marksans Pharma has shown consistent growth, with net sales increasing from INR 1,134.21 crore in March 2020 to INR 2,622.85 crore in March 2025, alongside rising profits and total assets. Despite a slight decrease in operating profit margin, the company has maintained positive cash flow from operations while investing in growth.

Answer:<BR>The historical performance of Marksans Pharma shows a consistent growth trajectory in key financial metrics over the years.<BR><BR>Breakdown:<BR>Marksans Pharma's net sales have steadily increased from INR 1,134.21 crore in March 2020 to INR 2,622.85 crore in March 2025, reflecting a strong upward trend. Total operating income has followed a similar pattern, rising from INR 1,000.07 crore in March 2019 to INR 2,622.85 crore in March 2025. The company's total expenditure, excluding depreciation, also grew significantly, reaching INR 2,090.16 crore in March 2025, up from INR 941.96 crore in March 2020. Operating profit (PBDIT) has shown a positive trend, increasing from INR 192.25 crore in March 2020 to INR 599.02 crore in March 2025, although the operating profit margin slightly decreased from 21.06% in March 2024 to 20.31% in March 2025. Profit before tax rose from INR 157.17 crore in March 2020 to INR 503.97 crore in March 2025, while profit after tax increased from INR 120.75 crore to INR 382.62 crore over the same period. The company's total assets have also expanded significantly, from INR 902.03 crore in March 2020 to INR 3,239.63 crore in March 2025, indicating robust growth in its financial position. Cash flow from operating activities has remained positive, with INR 206 crore in March 2025, although cash flow from investing activities has been negative, reflecting investments in growth. Overall, Marksans Pharma has demonstrated strong financial performance and growth across multiple dimensions.

Are Marksans Pharma Ltd latest results good or bad?

Marksans Pharma Ltd's latest Q3 FY26 results are positive, with a net profit increase of 15.22% QoQ and record revenue of ₹754.43 crore, alongside improved operating margins. However, the stock has declined 34.98% from its 52-week high, raising concerns about investor sentiment and future growth prospects.

Marksans Pharma Ltd's latest results for Q3 FY26 indicate a positive performance overall. The company reported a net profit of ₹113.20 crore, reflecting a 15.22% increase quarter-on-quarter (QoQ) and an 8.26% increase year-on-year (YoY). Revenue also saw a significant rise, reaching ₹754.43 crore, which is a 4.72% increase QoQ and a 10.64% increase YoY, marking the highest quarterly revenue in the company's history.<BR><BR>Additionally, the operating margin improved to 21.31%, up from 20.06% in the previous quarter, and the profit after tax (PAT) margin rose to 15.07%, indicating enhanced operational efficiency. These figures suggest a recovery from previous challenges, showcasing improved performance across key metrics.<BR><BR>However, despite these positive results, the stock has faced a notable decline of 34.98% from its 52-week high, which raises concerns about investor sentiment and valuation. The company has also experienced a significant drop in foreign institutional investor (FII) holdings, which may reflect broader concerns about its growth prospects.<BR><BR>In summary, while the latest results demonstrate strong operational improvements and record revenue, the stock's performance and investor sentiment indicate underlying challenges that could temper the overall assessment of the company's prospects.

Should I buy, sell or hold Marksans Pharma Ltd?

Which are the latest news on Marksans Pharma?

Why is Marksans Pharma Ltd falling/rising?

As of 08-Feb, Marksans Pharma Ltd's stock is at Rs 176.90, down 1.48%, and has significantly underperformed the market with a -34.29% return over the past year. Investor interest is waning, as indicated by decreased delivery volume and institutional stake reduction, contributing to a negative outlook despite some positive financial metrics.

As of 08-Feb, Marksans Pharma Ltd's stock price is falling, currently at Rs 176.90, reflecting a decrease of Rs 2.65 or 1.48%. The stock has underperformed its sector by 0.68% today and reached an intraday low of Rs 171.85, which is a decline of 4.29%. <BR><BR>Over the past year, the stock has generated a significant negative return of -34.29%, while the broader market, represented by the BSE500, has seen positive returns of 7.71%. This stark contrast indicates that Marksans Pharma Ltd has not only underperformed the market but also experienced a decline in profits by 2.2% during the same period. <BR><BR>Additionally, there are concerning trends in investor participation, as delivery volume has decreased by 16.66% compared to the 5-day average, suggesting a lack of interest among investors. Institutional investors have also reduced their stake by 8.16% in the last quarter, which may further contribute to the stock's downward pressure, as these investors typically have more resources to assess the company's fundamentals.<BR><BR>Despite some positive factors, such as a high return on equity (ROE) of 16.65% and a low debt-to-equity ratio, the overall outlook remains negative due to poor long-term growth prospects, as indicated by an operating profit growth rate of only 10.10% over the last five years and flat results in December. The stock's performance relative to moving averages also shows weakness, being lower than the 50-day, 100-day, and 200-day moving averages, which typically signals a bearish trend.